Antiviral agent and antiviral processed product containing the same

Abstract

To provide an antiviral agent having excellent antiviral property and an antiviral processed product containing the same.SOLUTION: Antiviral agents containing silver molybdate and zinc 2-ethylhexanoate have excellent antiviral properties. In addition, an antiviral processed product in which the antiviral agent is blended also has excellent antiviral properties, in particular, by blending 0.1 to 10 pts.mass of the antiviral agent to 100 pts.mass of the antiviral processed product, the antiviral properties become remarkable.SELECTED DRAWING: None

Description

Technical Field

[0001] The present invention relates to an antiviral agent and an antiviral processed product containing the same.

Background Art

[0002] Viruses having envelopes such as influenza virus and coronavirus, or viruses having no envelopes such as norovirus, cause various diseases. Therefore, antiviral compositions for controlling these viruses have been developed. (Patent Document 1)

Prior Art Documents

Patent Documents

[0003]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0004] An object of the present invention is to provide an antiviral agent having excellent antiviral performance and an antiviral processed product containing the same. Means for Solving the Problems

[0005] As a result of intensive studies to solve such problems, the present inventor has reached the present invention. That is, the present invention is 〔1〕An antiviral agent containing silver molybdate and zinc 2-ethylhexanoate. 〔2〕The antiviral agent according to the above, wherein the content of silver molybdate is 5 to 25% by weight based on the total content of silver molybdate and zinc 2-ethylhexanoate. 〔3〕An antiviral processed product containing the above antiviral agent. 〔4〕The antiviral processed product according to the above, wherein the above antiviral agent is blended in an amount of 0.1 to 10 parts by weight based on 100 parts by weight of the antiviral processed product. provided.

Effects of the Invention

[0006] According to the present invention, an object is to provide an antiviral agent having excellent antiviral properties and an antiviral processed product containing the same.

Best Mode for Carrying Out the Invention

[0007] Silver molybdate used in the antiviral agent of the present invention can be obtained, for example, by solid-liquid separation of a precipitate formed by mixing an aqueous solution of a silver salt and an aqueous solution of a molybdate, and drying the obtained wet precipitate. Examples of the silver salt include silver nitrate, silver acetate, silver sulfate, etc. Examples of the molybdate include sodium molybdate, potassium molybdate, ammonium molybdate, etc.

[0008] Zinc 2-ethylhexanoate used in the antiviral agent of the present invention can be obtained, for example, by metathesis of zinc sulfate and ammonium caprylate. Also, zinc 2-ethylhexanoate sold by Fuji Film Wako Pure Chemical Corporation, etc. can be used.

[0009] Since the property of zinc 2-ethylhexanoate at room temperature is a viscous liquid, it may be used by being supported on a carrier having an oil absorption amount of 1.5 to 5.0 ml / g (measured value according to JIS K5101-13-1). Examples of the carrier include calcium silicate and silicon dioxide having the above oil absorption amount. Examples of calcium silicate include Florite (registered trademark) R and RT (manufactured by Tomita Pharmaceutical Co., Ltd.), and examples of silicon dioxide include Toksil (registered trademark) NR (Oriental Silicas Corporation). When using it by supporting on a carrier, usually, the amount (weight / weight) of zinc 2-ethylhexanoate with respect to the carrier is set to 4 times or less.

[0010] The antiviral agent of the present invention preferably has a silver molybdate content in the range of 5 to 25% by weight based on the total content of silver molybdate and zinc 2-ethylhexanoate.

[0011] The antiviral agent of the present invention may be blended with a discoloration inhibitor, an ultraviolet absorber, etc. as necessary.

[0012] The antiviral agent of the present invention is blended into plastic agents such as resin films or sheets, coating agents such as paints and surface treatment agents, adhesives, fibers, papers, etc., and used as antiviral processed products. The antiviral agent of the present invention can exhibit excellent antiviral properties particularly when blended into a resin component.

[0013] Examples of such resin components include alkyd resins, polyester resins, acrylic resins, urethane resins, epoxy resins, fluororesins, silicone resins, unsaturated polyester resins, melamine resins, phenol resins, nitrocellulose resins, vinyl acetate resins, vinyl chloride resins, polyolefin resins, acrylonitrile-butadiene-styrene resins, and the like.

[0014] The blending amount of the antiviral agent of the present invention can vary depending on the material to be blended, but is usually 0.1 to 10 parts by weight per 100 parts by weight of the antiviral processed product.

[0015] The above-mentioned antiviral processed products are used for members related to the living environment such as wall materials, handrails, floor materials, wooden floor materials, kitchen counters, furniture, wallpapers, etc., members of electrical products such as the housings of refrigerators and air conditioners, fiber products such as filters, members related to electrical products such as the protective films of the image display parts of portable electronic devices, members related to industrial products such as the seats and floor mats of automobiles and trains, members related to packaging such as wrapping paper and cardboard, etc., and are each preferably used as various members having antiviral performance.

[0016] The antiviral in the present invention includes reducing the virus infection titer to reduce infectivity, suppressing the growth of the virus, and killing the virus.

Examples

[0017] Hereinafter, the present invention will be specifically described by formulation examples and test examples, but the present invention is not limited thereto.

[0018] (Preparation of silver molybdate) 430.0 g of ion-exchanged water was placed in a 1 L glass beaker, and 50.0 g of silver nitrate (manufactured by Fujifilm Wako Pure Chemical Corporation) was added thereto, followed by stirring and dissolution to prepare an aqueous silver nitrate solution. Also, 463.4 g of ion-exchanged water was placed in a 1 L separable round-bottom flask, and 36.6 g of sodium molybdate dihydrate (manufactured by Fujifilm Wako Pure Chemical Corporation) was added thereto, followed by stirring and dissolution to prepare an aqueous sodium molybdate solution.

[0019] Next, silver molybdate was precipitated by dropping the aqueous silver nitrate solution into the aqueous sodium molybdate solution with stirring. After the liquid containing silver molybdate thus obtained was suction filtered, the obtained filtrate was dried to obtain silver molybdate. Formulation Example 1

[0020] 1.0 g of zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Corporation, zinc octylate purity 99%) and 0.25 g of Florolite RT were mixed, and then 0.25 g of silver molybdate prepared above was further mixed to obtain an antiviral agent (hereinafter referred to as Formulation-1). Formulation Example 2

[0021] 1.125 g of zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Corporation, zinc octylate purity 99%) and 0.281 g of Florolite RT were mixed, and then 0.125 g of silver molybdate prepared above was further mixed to obtain an antiviral agent (hereinafter referred to as Formulation-2). Comparative Formulation Example

[0022] 0.25 g of the silver molybdate prepared above was used as a comparative formulation (hereinafter referred to as Comparative Formulation-1). Also, 1.0 g of zinc 2-ethylhexanoate (manufactured by Fujifilm Wako Pure Chemical Corporation, zinc octylate purity 99%) was used as a comparative formulation (hereinafter referred to as Comparative Formulation-2).

[0023] <Preparation of Test Specimens of Antiviral Resin Moldings> 100 g of ZEST-1300 (polyvinyl chloride, manufactured by Shin-Etsu Chemical Co., Ltd.), 45 g of diisononyl phthalate, 6.2 g of epoxidized soybean oil, and 12.3 g of stabilizer LBK-793K for vinyl resin (manufactured by Sakai Chemical Industry Co., Ltd.) were mixed and then kneaded at 170 °C using a lab plastomill to obtain a vinyl sol. 100 g of the vinyl sol and the formulation-1 were kneaded to obtain a resin compound. The resin compound was pressed at 180 °C using a press molding machine for 3 minutes and then cooled to room temperature to obtain a polyvinyl chloride sheet with a thickness of 0.5 mm. The sheet was cut into 5 cm × 5 cm to obtain test specimens. Two test specimens were prepared.

[0024] (Antiviral Test Against Influenza Virus) According to ISO21702, influenza virus H3N2 strain (influenza A virus: A / Hong Kong / 8 / 68: TC adapted ATCC VR-1679) was cultured using MDCK cells (dog kidney-derived cells) to obtain a test influenza virus suspension with a virus infectious titer of 2×10 7 Plaque Forming Unit / ml (hereinafter referred to as PFU / ml).

[0025] One of the above-mentioned test specimens was placed in a plastic petri dish, and 0.4 ml of the above-mentioned test influenza virus suspension was dropped onto the approximate center area of the test specimen. Then, a 4 cm square polyethylene film was placed to cover the entire test virus suspension, and it was stored at 25 °C and 95% humidity for 24 hours. Next, the test influenza virus suspension between the test specimen and the polyethylene film was washed out with 10 ml of SCDLP medium (manufactured by Nippon Pharmaceutical Co., Ltd.), and this washout solution was diluted 10-fold, 100-fold, 1000-fold, 10000-fold, and 100000-fold using EMEM medium. The influenza virus infectious titer (logarithmic value of IV infectious titer) was measured by the plaque assay method using MDCK cells.

[0026] (Antiviral Test Against Feline Calicivirus) According to ISO21702, the feline calicivirus F-9 strain (Feline calicivirus, Strain: F-9 ATCC VR-782) was cultured using CRFK cells (feline kidney-derived cells), and a test feline calicivirus suspension with a virus infectivity titer of 2×10 7 Plaque Forming Unit / ml (hereinafter referred to as PFU / ml) was obtained.

[0027] One test piece prepared above was placed in a plastic petri dish, and 0.4 ml of the above-mentioned test feline calicivirus suspension was dropped onto the approximate center area of the test piece. Then, a 4 cm square polyethylene film was placed to cover the entire test virus suspension, and it was stored at 25°C and 95% humidity for 24 hours. Subsequently, the test feline calicivirus suspension between the test piece and the polyethylene film was washed out with 10 ml of SCDLP medium (Nippon Pharmaceutical), and this washout solution was diluted 10-fold, 100-fold, 1000-fold, 10000-fold, and 100000-fold using EMEM medium (manufactured by Fujifilm Wako Pure Chemical Corporation). The feline calicivirus infectivity titer (logarithmic value of FCV infectivity titer) was measured for CRFK cells by the plaque measurement method.

[0028] For Formulation-2, Comparative Formulation-1, and Comparative Formulation-2, two test pieces were prepared in the same manner as above, and antiviral tests against influenza virus and feline calicivirus were carried out in the same manner as the above test.

[0029] The test results are summarized in Table 1.

[0030] [Table 1] Virus Infectivity Titer Measurement Results TIFF0007690199000001.tif3492

Claims

1. An antiviral agent containing silver molybdate and zinc 2-ethylhexanoate.

2. The antiviral agent according to claim 1, wherein the content of silver molybdate relative to the total content of silver molybdate and zinc 2-ethylhexanoate is 5 to 25% by weight.

3. An antiviral processed product comprising the antiviral agent according to claim 1 or claim 2.

4. The antiviral processed product according to claim 3, wherein the antiviral agent according to claim 1 or claim 2 is formulated in an amount of 0.1 to 10 parts by weight per 100 parts by weight of the antiviral processed product.

Images